(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

Patients with inadequate health insurance were more likely to receive mastectomy, omit RT following breast-conserving surgery, and receive PMRT. Differences in clinical presentation and demographics according to insurance status incompletely explain the variation in therapy. Further study is needed to validate and address these disparities and to evaluate the impact of health insurance legislative efforts in localized breast cancer.

Thomas M. Churilla, MD, Brian Egleston, PhD, Joshua Meyer, MD, Yanqun Dong, MD, PhD, Penny Anderson, MD; Fox Chase Cancer Center

INTRODUCTION: Various studies have suggested disparities in breast cancer care due to inadequate health insurance coverage. The purpose of our study was to test for associations between patient insurance status and the presentation and local therapy patterns among a large, nationally representative cohort of patients with localized breast cancer.

METHODS: We queried the National Cancer Institute (NCI) Survival, Epidemiology, and End Results (SEER) database for breast cancer cases diagnosed from 2007–2011 in women aged 18–64 years, limited to ductal or lobular histology, nonmetastatic stage, and treated with mastectomy or lumpectomy. Patients ≥ 65 years were excluded based on their eligibility for Medicare. We characterized clinical and demographic variables according to insurance status (insured vs Medicaid vs uninsured). We tested for associations between patient insurance status and choice of definitive surgical procedure (mastectomy vs breast-conserving surgery), omission of radiation therapy (RT) following breast-conserving surgery, and administration of postmastectomy RT (PMRT). We calculated odds ratios (ORs), performed Pearson’s chi-square test for univariable analysis, and used multiple logistic regression analysis to adjust for clinical and demographic covariates.

RESULTS: A total of 129,565 patients with localized breast cancer were analyzed. The health insurance statuses included insured (84.5%), Medicaid (11.5%), uninsured (2.1%), and unknown (1.9%). Patients with Medicaid or uninsured status were more likely to present with large, node-positive tumors and be black or unmarried and reside in low-income counties. The breast-conserving surgery rate was 51.3% among all patients and varied according to insurance status: insured (52.2%), uninsured (47.7%), and Medicaid (45.2%) (P < .001). Medicaid insurance status remained significantly associated with receipt of mastectomy in the multivariable analysis (OR =1.07; 95% confidence interval [CI], 1.03–1.11; P < .001). Radiation therapy was more frequently omitted after breast-conserving surgery in both Medicaid (OR = 1.14; 95% CI, 1.07–1.21) and uninsured (OR = 1.29; 95% CI, 1.14–1.47) patients in the multivariable analysis (P < .001 for both). PMRT was more frequently administered among Medicaid and uninsured patients; however, only Medicaid status remained significantly associated with PMRT in the multivariable analysis (OR = 1.10; 95% CI, 1.04–1.18; P = .002).

CONCLUSION: Patients with inadequate health insurance were more likely to receive mastectomy, omit RT following breast-conserving surgery, and receive PMRT. Differences in clinical presentation and demographics according to insurance status incompletely explain the variation in therapy. Further study is needed to validate and address these disparities and to evaluate the impact of health insurance legislative efforts in localized breast cancer.

Proceedings of the 97th Annual Meeting of the American Radium Society -americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Recent Videos
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Although accuracy remains a focus in whole-body MRI testing in patients with Li-Fraumeni syndrome, comfortable testing experiences may ease anxiety.
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.
Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.
Related Content